Aspen Pharmacare (APNHY)
(Delayed Data from OTC)
$10.92 USD
0.00 (0.00%)
Updated Sep 20, 2024 12:47 PM ET
NA Value
NA Growth NA Momentum NA VGMBalance Sheet
Fiscal Year End for Aspen Pharmacare falls in the month of June.
All items in Millions except Per Share data.
6/30/2024 | 6/30/2023 | 6/30/2022 | 6/30/2021 | 6/30/2020 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 660 | 615 | 407 | 557 | 457 |
Receivables | 735 | 789 | 830 | 697 | 852 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | 963 | 1,106 | 1,037 | 874 | 1,057 |
Other Current Assets | NA | 0 | 0 | 4 | 0 |
Total Current Assets | 2,359 | 2,510 | 2,274 | 2,132 | 2,366 |
Net Property & Equipment | 1,067 | 1,043 | 1,047 | 967 | 917 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | 96 | 89 | 82 | 86 | 110 |
Intangibles | 3,842 | 3,875 | 3,860 | 3,880 | 5,050 |
Deposits & Other Assets | 51 | 34 | 45 | 60 | 95 |
Total Assets | 7,445 | 7,574 | 7,328 | 7,151 | 8,576 |
Liabilities & Shareholders Equity | 6/30/2024 | 6/30/2023 | 6/30/2022 | 6/30/2021 | 6/30/2020 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | 554 | 574 | 662 | 601 | 624 |
Current Portion Long-Term Debt | 605 | 446 | 768 | 1,604 | 406 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 0 | 0 | 0 | 0 |
Income Taxes Payable | 42 | 51 | 40 | 0 | 0 |
Other Current Liabilities | 103 | 235 | 70 | 191 | 134 |
Total Current Liabilities | 1,304 | 1,306 | 1,539 | 2,396 | 1,164 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 85 | 113 | 129 | 118 | 174 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | 1,345 | 1,206 | 696 | 17 | 2,320 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 171 | 86 | 295 | 341 | 461 |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | 2,905 | 2,710 | 2,660 | 2,873 | 4,119 |
Shareholders Equity | 6/30/2024 | 6/30/2023 | 6/30/2022 | 6/30/2021 | 6/30/2020 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | 88 | 94 | 117 | 122 | 122 |
Capital Surplus | NA | 0 | 0 | 0 | 0 |
Retained Earnings | 4,452 | 3,279 | 3,576 | 4,157 | 2,957 |
Other Equity | NA | 1,491 | 975 | 0 | 1,378 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 4,540 | 4,864 | 4,668 | 4,279 | 4,458 |
Total Liabilities & Shareholder's Equity | 7,445 | 7,574 | 7,328 | 7,151 | 8,576 |
Total Common Equity | 104,539 | 4,864 | 4,668 | 4,279 | 4,458 |
Shares Outstanding | NA | 446.20 | 446.20 | 456.40 | 456.40 |
Book Value Per Share | -1.05 | 10.90 | 10.46 | 9.38 | 9.77 |
Fiscal Year End for Aspen Pharmacare falls in the month of June.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,339 | -99,999 | -99,380 | -99,999 | 615 |
Receivables | 735 | NA | 719 | NA | 789 |
Notes Receivable | NA | NA | NA | NA | 0 |
Inventories | 963 | NA | 1,012 | NA | 1,106 |
Other Current Assets | NA | NA | NA | NA | 0 |
Total Current Assets | 2,359 | NA | 2,351 | NA | 2,510 |
Net Property & Equipment | 1,067 | NA | 1,027 | NA | 1,043 |
Investments & Advances | NA | NA | NA | NA | 0 |
Other Non-Current Assets | NA | NA | NA | NA | 0 |
Deferred Charges | 96 | NA | 78 | NA | 89 |
Intangibles | 3,842 | NA | 3,932 | NA | 3,875 |
Deposits & Other Assets | 51 | NA | 30 | NA | 34 |
Total Assets | 7,445 | NA | 7,438 | NA | 7,574 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | NA | NA | NA | 0 |
Accounts Payable | 554 | NA | 565 | NA | 574 |
Current Portion Long-Term Debt | 605 | NA | 619 | NA | 446 |
Current Portion Capital Leases | NA | NA | NA | NA | 0 |
Accrued Expenses | NA | NA | NA | NA | 0 |
Income Taxes Payable | 42 | NA | 30 | NA | 51 |
Other Current Liabilities | 103 | NA | 11 | NA | 235 |
Total Current Liabilities | 1,304 | NA | 1,225 | NA | 1,306 |
Mortgages | NA | NA | NA | NA | 0 |
Deferred Taxes/Income | 85 | NA | 100 | NA | 113 |
Convertible Debt | NA | NA | NA | NA | 0 |
Long-Term Debt | 1,345 | NA | 1,309 | NA | 1,206 |
Non-Current Capital Leases | NA | NA | NA | NA | 0 |
Other Non-Current Liabilities | 171 | 233 | NA | 86 | |
Minority Interest (Liabilities) | NA | NA | NA | NA | 0 |
Total Liabilities | 2,905 | NA | 2,867 | NA | 2,710 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | NA | NA | NA | 0 |
Common Stock (Par) | 88 | NA | 88 | NA | 94 |
Capital Surplus | NA | NA | NA | NA | 0 |
Retained Earnings | 4,452 | NA | NA | NA | 3,279 |
Other Equity | NA | NA | 4,483 | NA | 1,491 |
Treasury Stock | NA | NA | NA | NA | 0 |
Total Shareholder's Equity | 4,540 | NA | 4,571 | NA | 4,864 |
Total Liabilities & Shareholder's Equity | 7,445 | NA | 7,438 | NA | 7,574 |
Total Common Equity | 104,539 | 0 | 104,570 | 0 | 4,864 |
Shares Outstanding | NA | 446.20 | 446.20 | 446.20 | 446.20 |
Book Value Per Share | -1.05 | 0.00 | 234.36 | 0.00 | 10.90 |